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Previous Treasury research has identified “price and coverage” effects as playing a key 
role in the growth of historical health expenditure. This incorporates factors such as 
technological change and input prices including wages. Bryant et. al. (2004) found that 
between 1950-51 and 2001-02, growth in price and coverage effects was the main source 
of long run growth in government health expenditure and has accounted for 3-4% growth 
per year since the early 1990s.  
This paper explores how a new health technology diffuses across District Health Boards 
(DHBs), the price and coverage effects, and whether access is evenly spread across the 
population i.e. who benefits from a new device or procedure.  
In particular, it highlights: 
•  the variation in clinical practice between different DHBs 
•  the degree to which the adoption of a particular technology in one DHB impacts on 
neighbouring DHBs: 
−  a “domino” effect occurs when the adoption of a technology in one DHB leads to 
other DHBs following suit   
−  the adoption of a technology in one DHB leads to increased inter-district flows 
between DHBs. 
•  differences in access between geographical regions and also ethnic groups 
The paper takes the example of a new procedure used in coronary care known as 
‘stenting’ and examines its adoption across the different DHBs. Data used pertains to 
different heart procedures adopted across New  Zealand over a particular time frame 
(1995-2004). It comprises patient details plus information relating to the DHB in which the 
procedure was carried out and also the patient’s domicile DHB.  
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Investigating Health Technology 
Diffusion in New Zealand – How Does 
it Spread and Who Stands to Gain? 
1  Introduction and Motivation 
International evidence (Australian Productivity Commission Report, 2005
1
) has identified 
advances in technology as a key driver of health spending. However, the overall impact of 
a particular innovation remains ambiguous. First, there is the issue of incentives facing 
each party in question and the regime under which decision makers operate. For instance 
high levels of regulation may act as a deterrent to the spread of new technology. Second, 
new technologies typically have both price and coverage effects whereby an advance in 
technology may reduce the cost of a particular outcome but broaden the scope of patients 
who can receive the treatment. Consequently, a number of factors influence the spread of 
technologies across a health sector.  
This paper explores how a new health technology diffuses across District Health Boards 
(DHBs), the price and coverage effects, and whether access is evenly spread across the 
population i.e. who benefits from a new device or procedure. In doing so it also reveals a 
number of general issues in the health sector such as differences in policy settings and 
funding arrangements. These can contribute to:  
•  a variation in clinical practice between different DHBs; 
•  a differing degree to which the adoption of a particular technology in one DHB 
impacts on neighbouring DHBs: 
−  a “domino” effect occurs when the adoption of a technology in one DHB leads to 
other DHBs following suit   
−  the adoption of a technology in one DHB leads to increased inter-district flows 
between DHBs; and 
•  differences in access between geographical regions and also ethnic groups. 
The paper takes the example of a new procedure used in coronary care known as 
‘stenting’ (described later in the glossary of terms) and examines its adoption across the 
                                                                  
1   The report cites a number of other studies from Australia, US and UK which measure the impact of technology through a residual 
from using a regression based analysis. These include Wanless (2001) and Newhouse (1992).  
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different DHBs. Data used pertains to different heart procedures adopted across 
New Zealand over a particular time frame (1995-2004). It comprises patient details plus 
information relating to the DHB in which the procedure was carried out and also the 
patient’s domicile DHB.    
This investigation first sets out the literature describing technology diffusion as it relates to 
coronary care and hence what might be expected with regards to the New Zealand case. 
The data is then outlined in Section 3 with key results following in Sections 4 and 5. These 
are used to formulate policy issues in the concluding section. 
2  Literature – What determines health 
technology diffusion? 
An international body of work already exists that seeks to explain the diffusion of health 
technologies across countries i.e. why some adopt a procedure sooner than others 
(McLellan and Kessler, 1999). A number of incentives were identified which influence the 
process of technological change: 
•  The degree to which costs are borne by patients – Substantial out of pocket 
payments put a limit on technological growth. 
•  Generosity of payments to hospitals – Fixed global budgets are associated with a 
strong limit on technological growth whereas fee-for-service payments have the 
opposite effect. 
•  Generosity of payments to physicians – Where physicians are mainly salaried, 
technological growth is slow. When fee-for-service payments are offered there is a 
much greater incentive to adopt new technologies. 
•  “Micro” technology regulation – Countries that require extensive reviews of 
individual treatment decisions put a strong limit on technological growth. Those 
needing little or no case-level review area associated with fewer barriers to 
technological change.   
2.1  The New Zealand Experience  
2.1.1  Policy settings provide a starting point for understanding 
health technology in New Zealand… 
How we configure our health services in New Zealand is determined in part by our 
geography. With a population equivalent to the size of a major overseas city yet relatively 
dispersed over a large geographical area, we face a particular set of circumstances.  
New pharmaceuticals are reviewed by PHARMAC and hence barriers to diffusion exist 
here. However, the process for approving and adopting other technologies involving large 
new pieces of equipment or service reconfigurations is still in its infancy. In May 2005, the 
National Health Committee put together a report to the Minister of Health setting out 
recommendations for a health intervention process (Decision Making about New Health 
Interventions, 2005). The Ministry of Health and DHBNZ have subsequently put into place 
the Service Planning and New Health Intervention Assessment (SPNHIA). The new 
procedures call for a more collaborative decision making process between DHBs, the  
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Ministry of Health and other related bodies. Capital allocation is also considered and if the 
new technology requires it, then a separate set of guidelines exists for capital investment 
(Ministry of Health 2003 and 2005) once the technology has been approved by SPNHIA.     
2.1.2  But the role of budgeting and funding arrangements must 
not be overlooked. 
Related to the above section outlining current policy settings is the notion of budgeting 
and funding arrangements. The data used in this investigation spans a period which 
incorporates a number of different funding arrangements. Between 1991 and 1997 
responsibility for purchasing health services shifted from local purchasing (with 14 area 
health boards) to regional purchasing (under 4 regional health authorities) to central 
purchasing with a single health funding authority. In 2001 District Health Boards came into 
existence each of which has a role in planning, funding, and providing health services for 
respective district populations. There are 21 in total and a large fraction of health funding 
is channelled through them.  
This has implications for the adoption and dissemination of new technologies. Despite the 
lack of evidence on long term efficacy, the number of stents performed in New Zealand 
has increased dramatically since their introduction in 1995. In part, this may be explained 
by the manner with which they are funded e.g. if interventional cardiology services such 
as angioplasty and stents draw on different resources or silos from cardiac surgery (e.g. 
coronary artery bypass grafts, henceforth known as CABGs) then this may help to explain 
the rapid growth in one procedure.   
Given that the 21 DHBs each have their own funding and provider roles, it is inevitable 
that there will be different views between DHBs on how best to fund similar services. 
Consequently, one would expect differences over time in how services are funded and 
purchased. However, this also has the potential to generate opportunities for some 
providers to leverage enhanced clinical capability particularly when the people using the 
new technology in their procedures are the same ones promoting it.  Some commentators 
argue that this is the situation facing cardiology in New Zealand and that in this 
environment, clinicians and funders would appreciate information from technology 
assessment groups to advise on emerging technologies in the field. 
2.1.3  Investing in new cardiac treatments carries a risk since it 
comes with high fixed or variable costs… 
High Technology Treatments are those with high fixed costs or high variable costs per 
use. Many cardiac procedures fall into this category since they require substantial set up 
costs by hospitals in hiring specialised personnel (e.g. interventional cardiologists) and 
purchasing specialised equipment (e.g. catheterisation tables and fluoroscopes). Notably, 
it has been found that countries using fixed provider payments had relatively little growth 
in the use of these invasive procedures. (McClellan and Noguchi, 1998). 
2.1.4  …but successful new innovations in cardiology are highly 
regarded by international clinicians. 
In a recent survey, 225 leading general internists in the US were asked to rank the relative 
importance to patients of thirty medical innovations (Fuchs and Sox, 2001). The results 
put Balloon Angioplasty with Stents in 3
rd place with Coronary Artery Bypass Grafts  
WP 06/05   
INVESTIGATING HEALTH TECHNOLOGY DIFFUSION IN 





th.  This is not surprising given the high incidence of cardiovascular disease in 
the US and hence a significant “ability to benefit” in the population. Given that 
New Zealand faces similar pressures we might expect our rankings to be much the same 
as those in the US. 
2.1.5  So with limited information on the spread of new 
technologies across New Zealand, there is a need to look 
further afield. 
Despite the growing interest in technology diffusion, very little information exists that 
examines the spread of technology across regions within a country and no work to date 
has looked at health technology diffusion between the different DHBs of New Zealand. 
There is, however, considerable anecdotal evidence that can be tested against the data 
and a preliminary analysis provided by James Harris (2005) from a seminar entitled 
“Changing Priorities: Stents in Cardiovascular Care”. 
While Harris’s work did not focus explicitly on the spread of a technology across 
New Zealand’s DHBs, it did reveal some problems encountered when a new technology is 
first introduced into an area, drawing comparisons with the Australian case. 
His paper revealed that the process for adopting new technologies has differed between 
Australia and New Zealand. Australia did not fund the newer forms of stent devices until 
they were approved by the national Medical Services Advisory Committee (MSAC). The 
first drug eluting stents (DES) were added to the Australian Register of Therapeutic 
Goods (ARTG) as a non-current entry in 2000-01. This was conditional on the drug that 
coated the stent being approved for treating coronary heart disease. The approval was 
granted by the Therapeutics Goods Administration in June 2002. In 2005, MSAC carried 
out an assessment of DES for the Health Policy Advisory Committee. It was determined 
that the procedure was safe and more cost effective than bare metal stents mainly 
because it reduces rates of revascularisation at up to one year post procedure. However, 
it stressed that additional clinical practice data was needed since it was still early days 
with regard to the use of this device. In the same year, the Australian Productivity 
Commission Report outlined possible long term problems associated with these stents 
such as inflammatory responses and thrombotic reactions.   
By contrast, New Zealand has not carried out national assessments, and has arguably 
weaker national controls over the details of hospital spending than Australia. Most health 
purchase choices are made locally at the DHB level with DHB funding and planning arms 
controlling provider arm spending within a budget set by ministers given district annual 
plans and district strategic plans. Until recently, New Zealand has effectively delegated 
decisions on devices and procedures to clinicians. After being introduced in New Zealand 
in 1995, stenting quickly became a popular procedure. However, when the newer drug 
eluting stents were introduced in 2002/03 their use became confined to particular 
hospitals and DHBs because of their cost and the lack of established clinical data 
supporting their use in New Zealand. This is relevant when we consider the following cost 
information.   
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Table 1 – A Comparison of Individual Costs and Total Expenditure on Different 
Interventions 
  Unit Cost  Total Cost  - 2002 
(millions of dollars) 
CABG $21  400  42.7 
PTCA $6  300  2 
Stent $6  900  20.4 
Source: Harris (2005). Note that PTCA refers to percutaneous transluminal coronary angioplasty. 
2.1.6  The use of bare metal stents has not been a substitute for 
the more expensive existing technologies…  
If PTCAs and Stents were perfect substitutes for CABGs we would expect the number of 
CABGs to decrease while the number of stents and PTCAs would increase by the same 
proportion. Equally, expenditure on coronary care would be considerably reduced from the 
improvement in technology. This has not been supported by the data. Indeed, 
examination of more recent data finds that CABGs have been on the increase. This is 
seen in Figure 1 showing the number of admissions to New Zealand hospitals for the 
period 1990-2004 for each procedure. 
The fact that we do not see this substitution effect suggests that the existence of stents 
has increased the number of candidates receiving an intervention. An obvious inference is 
that patients with low clinical complexity who in the past may not have had an intervention 
of any kind are now prime candidates for a stent hence the increase in numbers. 
Moreover, these procedures are performed by an interventional cardiologist and are 
stimulating and rewarding to do. There is then an incentive for more to be done to seek 
suitable candidates thus increasing the pool of patients treated for coronary artery 
disease.  
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Source: NZHIS (2005) 
Note: The data is expressed here in terms of calendar years but represents data from mid 1990 to 
the end of the 2003-04 financial year. The observed decline in 2004 is because we have only 
included six months of data for that year. 
2.1.7  …because the procedures are not interchangeable  
Wellington cardiologists stressed that clinicians cannot substitute CABG with angioplasty 
since there are many instances where CABG is the more appropriate (and safer) option. 
This depends on: 
•  the number of vessels which are involved; 
•  the distance over which the artery has narrowed; 
•  whether the patient has experienced a heart attack in the past; and 
•  the size of the blockage. 
Therefore continued use of CABG is not necessarily a sign of a lack of technology 
diffusion but may also reflect the conditions presented by patients. Hence any analysis of 
new technology uses must also take into account the change in clinical complexity of each 
case.  
Notably, when the health literature debated the relative efficacy of CABGs and stents 
(Hannan et al. 2005, Hill et. al. 2004, Weinstein 2003, to name just a few), the general 
view was that stenting was suitable for patients with low clinical complexity or limited 
disease. A number of studies have pointed to the fact that it is wrong to look at stenting as 
a “one off” procedure and then compare costs with a CABG since people could have  
WP 06/05   
INVESTIGATING HEALTH TECHNOLOGY DIFFUSION IN 




multiple stents before finally coming up for a CABG. It may therefore be better to think of 
stenting as a strategy rather than a single procedure.  
Furthermore, technology has advanced not just in the nature of the devices (e.g. drug 
eluting stents versus bare metal stents) but also in surgical advances which allow stents 
to be used in places not previously reachable. Moreover, new technologies enable 
clinicians to treat people who could not be treated with the older technologies. 
Consequently, while the cost of a heart operation may fall with advances in technology, 
the number of people treated increases dramatically thus driving up overall expenditure in 
the cardiology area.  
2.1.8  The evidence on drug eluting stents is inconclusive 
because the device has only recently been introduced so 
advisory committees are acting with caution… 
Drug eluting stents (DES) have only been used in New Zealand for the past 3 years and 
are subject to considerable controversy. The actual DES costs on average $5800 while 
bare metal stents are considerably cheaper at $950. Hence in the absence of international 
evidence showing outcome advantages for the DES, the bare metal stent would appear 
more cost effective. However, anecdotal evidence suggests DES have been adopted 
around New Zealand on the basis of individual judgement so that now, some cardiologists 
adopt the DES while others stick with the bare metal stent. Evidence from one DHB 
suggests that there are discrepancies with the use of drug eluting and bare metal stents 
between neighbouring DHBs. The benefits of using the more expensive drug eluting 
stents are not conclusive (despite the MSAC findings). Hence some DHBs are opting for 
bare metal stents in their surgery. However, other DHBs have already adopted the use of 
drug eluting stents, perhaps because they do not face such tight funding constraints.   
The controversy concerns the manner with which this dissemination took place. The DES 
was not required to pass a clinical trial in New Zealand before being taken into practice. 
Given its cost and concern over the drug coating of the DES (i.e. possible long term 
problems outlined in the Australian Productivity Commission Report, 2005), this questions 
the process through which new technologies are introduced into New Zealand hospitals. 
In terms of the data presented here, the International Classification of Diseases (ICD9) 
makes no distinction between drug eluting and bare metal stents so we cannot see the 
extent to which one type is used instead of another hence our comments are based on 
anecdotal evidence from practitioners in different DHBs. 
2.1.9  …but there are a number of factors influencing its 
adoption. 
Influence of the patient – Anecdotal evidence suggests that as patients become more 
well-informed through media or internet, they tend to pressure clinicians for particular 
procedures. This makes it even more difficult to reverse the trend of a relatively “poor” 
technology (e.g. less cost effective than alternative choices) in the absence of robust 
research which may not become available in the short term. 
Staffing – Interventional cardiologists and specialised nurses are typically attracted to 
those DHBs with a specialised research-oriented hospital (such as Capital and Coast 
District Health Board, Waikato District Health Board and Canterbury District Health  
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Board). Conversely, it is very difficult to attract skilled staff in isolated hospitals outside 
these DHBs, which may generate inequalities. However, this is not necessarily a bad thing 
if: (a) a particular safety threshold exists for the number of procedures performed by a 
cardiologist in a certain time frame; or (b) it is costly to perform only a few such 
procedures in an institution. Sadly, the data does not decompose to individual clinicians. 
Nevertheless, it does show each facility (e.g. hospital) in which the procedure is carried 
out. This means that we can get an idea of the volume of patients treated in a hospital 
over a particular time period.  
Domino effects and Inter-district flows 
With regard to technological diffusion, problems exist between neighbouring DHBs. For 
instance it has been suggested that if Capital and Coast decided to take up the procedure 
of offering drug eluting stents, Hutt Valley would feel the impact through increased inter-
district flows. Work has started in New  Zealand to make comparisons across DHBs 
(Sharpe and Wilkins, 2004) in order to ensure quality and equity in cardiovascular health 
across the country. Initial results suggest that inequalities do indeed exist particularly 
when comparing between those hospitals regarded as “intervention” centres and those 
that are not. The examples used in their study were Waikato and Taranaki hospitals. 
Significantly higher revascularisation rates were seen at Waikato where management was 
performed by cardiologists with immediate access to invasive intervention facilities. It is a 
subject for debate as to whether decision making should take this form (Conaglen et al. 
2004). As may be expected, some DHBs cannot afford to take on new technologies. 
Consequently, technological diffusion may be strongly influenced by the degree to which 
the DHB is funding constrained. 
3 Data 
The study uses data taken from New Zealand Health Information Service (NZHIS) that 
includes any patients who underwent one of the procedures outlined in Table 2. Notably 
this does not consider patients using the private sector. As such, the figures do not tell a 
complete story about national intervention rates but only what is happening in the public 
sector. The codes follow the International Classification of Diseases (ICD9) and are 
consistent with other recent investigations into cardiac services in New Zealand (Doolan-
Noble, Broad, Riddell and North, 2004). Notably it runs from mid 1990 to mid-way through 
2004 (which represents the end of the financial year, 2003/04), hence calendar years 
1990 and 2004 do not constitute a full year of data.  
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Table 2 – Procedure Codes Used in Data Analysis 
Code  Procedure 
3601  Single vessel PTCA without mention of thrombolytic agent 
3602  Single vessel PTCA with thrombolytic agent 
3603  Open chest coronary artery angioplasty 
3604  Intracoronary artery thrombolytic infusion 
3605  Multiple vessel PTCA performed during single operative episode 
3606  Dilation/stenting of single coronary vessel 
3607  Dilation/stenting of multiple coronary vessels 
3609  Other removal of coronary artery obstruction 
3610  Aortocoronary bypass for heart revascularization, NOS 
3611  Aortocoronary bypass of one coronary artery 
3612  Aortocoronary bypass of two coronary arteries 
3613  Aortocoronary bypass of three coronary arteries 
3614  Aortocoronary bypass of four or more coronary arteries 
3615  Single internal mammary-coronary artery bypass 
3616  Double internal mammary-coronary artery bypass 
3619  Other bypass anastomosis for heart revascularisation 
4  The Big Picture – Results from the Entire 
Sample (Stents, Angioplasty and CABG) 
4.1.1  After their introduction in 1995, the use of stents increased 
rapidly but the number of admissions for a CABG also 
continued to rise. 
The data in Table 3 is reproduced in Figure 1 of Section 2. Notably, there is a sharp 
increase in the use of stents after their introduction in 1995 but a steady increase in the 
number of admissions for a CABG. This is consistent with the hypothesis that bypasses 
are now being performed on patients who may not have received that treatment a decade 
ago. Advances in other areas of technology such as anaesthetics have enabled other 
groups to safely undergo this procedure.   
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Table 3 – No. of Admissions for Stents, Angioplasty and Bypass Grafts 
Year  Stents  PTCA + Stents  PTCA  CABG 
1990     339 643 
1991     702  1257 
1992     797  1162 
1993     1022 1274 
1994     1131 1206 
1995  9  217 1179 1414 
1996 154  427  917  1378 
1997 999  152  674  1606 
1998 1348  158  426  1680 
1999 1989  130  371  1760 
2000 2296  64  393  1962 
2001 2717  65  347  1964 
2002 2933  59  308  1971 
2003 3325  58  203  1865 
2004 1817  25  91  820 
4.1.2  The average age of patients increased across the period 
and their length of stay in hospital reduced… 
Table 4 – Average Age of All Admissions for Cardiac Procedures between 1990 and 
2004 
  Average Age  Length of Stay 
1990 59.89  11.78 
1991 60.19  11.08 
1992 60.39  10.43 
1993 60.88  9.89 
1994 60.88  9.47 
1995 61.21  8.85 
1996 61.49  8.72 
1997 62.47  8.23 
1998 62.35  8.16 
1999 62.51  7.53 
2000 62.66  7.42 
2001 63.12  6.80 
2002 63.13  6.70 
2003 63.25  6.61 
2004 63.02  6.59 
Table 4 is supportive of the hypothesis that more risky patients are being treated. The 
table shows very broadly the average age of patients undergoing any of the procedures 
across the period. In a period of 14 years this average has risen by just under 4 years. 
Alongside this, the average length of stay in hospitals has dropped from 11.8 days in 1990 
to 6.6 days in 2004.   
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4.1.3  …but the benefits of the technology are not equally 
distributed across all sections of the community. 
At first glance the evidence appears favourable. It seems that New  Zealanders have 
experienced an increase in access to these procedures. The number of operations has 
gone up together with the average age of people being treated. However, we need to 
ascertain whether these technological advances are being equally spread across the 
entire community by looking at the age, ethnicity and domicile of the people undergoing 
the operations. We also need to see whether this increase in output is achieved across all 
facilities.  
Table 5 – Ethnic Group of Each Patient 
Ethnic Group  Number of Admissions  % of Total 
NZ European  38911  78.02 
Other European  3399  6.82 
NZ Maori  2229  4.47 
Other 1751  3.51 
Indian   907  1.82 
European Not Further Defined  524  1.05 
Not stated  521  1.04 
Samoan 377  0.76 
Chinese 262  0.53 
Fijian 194  0.39 
Other Asian  155  0.31 
Cook Island Maori  142  0.28 
Tongan 126  0.25 
Niuean 96  0.19 
Middle Eastern  85  0.17 
Other Pacific Island  63  0.13 
South East Asian  35  0.07 
African 31  0.06 
Asian not further defined  27  0.05 
Tokelauan 18  0.04 
Pacific Island Not further defined  15  0.03 
Latin American/Hispanic  5  0.01 
Total 49873   
Clearly the largest group to undergo the cardiac procedures listed are NZ Europeans at 
78% of the sample with NZ Maori accounting for just 4%. Given that Maori males have an 
age standardised heart disease mortality rate 65.5% higher than non-Maori, one would 
have expected this figure to be greater if access were the same for all (See Table 6). 
According to Statistics New  Zealand, the Maori population account for 14.1% of the 
population and Pacific Island people make up 6.2%. The fact that they are under 
represented here raises issues of accessibility and equity. The Ministry of Health has long 
stressed the importance of tackling cardiovascular disease particularly with regard to 
Maori and Pacific Island people and has devised ongoing programs to improve knowledge 
in the area (New Zealand Health Strategy, DHB Toolkit, Cardiovascular Disease – To 
reduce the incidence of cardiovascular disease, 2003). With many of these policies 
geared towards the long term, one would not expect instant reductions in the mortality  
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rate. But the observed difference in access suggests that it would be useful to monitor 
future numbers in each major ethnic group receiving coronary procedures.  
Table 6 – Numbers and Rates of Death from Ischaemic Heart Disease by Sex and 
Ethnicity, 1999-2001 
1999  2000  2001   
No.  Rate  No.  Rate  No.  Rate 
Male  347 233.7  308 201.4  285 176.7  Maori 
Female 207  129.1 195  113.8 209  119.0 
Male  3299 121.9 2961 106.8 3104 106.8  Non-
Maori  Female 2718  56.9 2509  51.5 2773  54.3 
Male  3646 130.7 3269 114.1 3389 112.8  Total 
Female 2925  61.9 2704  55.7 2982  59.0 
Source:   Mortality and Demographic Data 2001, New Zealand Health Information Service, Table 17, Page 22.Note: The rates are 
per 100000, age standardised to Segi’s world population 
Of further interest is the gender balance. Males accounted for 73% of admissions while 
females accounted for 27%. However, this is consistent with the mortality data produced 
by the NZHIS (Table 6). Age standardised death rates for ischaemic heart disease were 
112.8 per 100 000 for men and 59 per 100 000 for women.  
4.1.4  And the age-standardised mortality rate has not decreased 
for all groups in society. 
Table 6 also illustrates the age-standardised mortality rate over time. Notably it only 
incorporates data for the years 1999 to 2001 and hence there are only 3 data points for 
each series. Nevertheless it shows that mortality rates do not drop for ischaemic heart 
disease for all groups within the sample. Clearly mortality rates are related to a number of 
factors of which technology is only one.  
4.1.5  Inter-district flows become an issue when new technology 
is not widely disseminated 
It is important to establish where people live in relation to the place where they receive 
treatment. Appendix Table 1 (attached) shows the domicile DHB for each of the 49873 
admissions in the sample alongside the agency providing the service. This provides 
information regarding inter-district flows and stresses the importance of correctly pricing 
hospital procedures. 
Appendix Table 1 shows that there are 5 main DHB centres for the cardiac procedures; 
Auckland; Waikato; Capital and Coast; Otago; and Canterbury. Naturally, patients 
domicile to these DHBs generally have their operations performed there. What is of 
interest, are those patients living outside the main centres. For example, Hutt Valley, Mid 
Central and Hawkes Bay people are predominantly treated by neighbouring Capital and 
Coast; Tairawhiti patients are treated by Waikato DHB; and Southland patients are treated 
by Otago DHB. The numbers suggest a substantial inter-district flow towards the main 
centres.   
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5  Disaggregating the Data – Results from 
Individual Procedures, DHBs and Hospitals  
Disaggregating the data allows us to look at the individual procedures across different 
DHBs and hospitals. This is particularly useful for examining the extent to which 
populations in each region have access to both new and well established technologies. 
5.1.1  Maori and Pacific Island people are not well represented in 
the sample but the ethnicity mix is changing over time for 
certain regions. 
The aggregate data suggest that ethnic groups other than NZ European are 
underrepresented. However, the disaggregated data provide a richer story. Table 7 
decomposes stent procedures (i.e. a new technology) for each DHB based on patient age, 
gender, and ethnicity. Figures for Auckland, Canterbury and Waikato show a reduction in 
the proportion of patients who are NZ European with figures for the remaining DHBs 
showing no significant change.  
Table 7 – Decomposing Stent Procedures by Patient Type 
DHB    1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
Age  58.8 61.2 60.6 59.9 59.8 60.4 61.5 62.2 61.2 61.7 
Gender  75  68 75.6 68.6 73.6 71.2 72.5 68.3 73.8 73.8 
Auckland 
 
Ethnicity  82.4 85.7 84.9 80.4 74.4 68.4  68 65.4 59.3 56.3 
Age  56.7 58.6 60.1 61.9 61.4 62.1 61.6 61.5 61.9 61.3 
Gender  100 67.2 72.2 73.1 66.2 68.6 70.7 67.3 73.4 73.1 
C & C 
Ethnicity  100 65.7  66 70.8 66.2 74.7 73.5 73.8 72.6 69.1 
Age  63.2 58.4 61.1 61.2 61.3 61.8 62.8 63.1 64.6 63.8 
Gender  69.1 78.9 71.5 71.4 69.6 68.8 69.6 68.1 68.9 72.8 
Otago 
Ethnicity  81.8 85.6 80.1 87.4 87.5 83.4 84.6 83.6 82.1 83.2 
Age  58.2 57.8 59.3 60.2 62.3 61.7  62 60.7 61.7 62.2 
Gender  77.8 74.4  76 68.7 64.4 68.9 69.9 73.8  70 70.9 
Waikato 
Ethnicity  77.8 83.7  86 79.1 79.7 76.7 74.2 75.2 77.8 76.2 
Age  75  58 54.2 60.4 62.6  63 62.6 62.1 63.4 63.1 
Gender  100  100 83.3 69.9  70 66.5 67.7  71 71.2 68.5 
Canterb. 
Ethnicity  0  100 83.3 82.1 80.5 76.5  74 70.1 70.5 69.4 
Age      57 59.3 55.4 56.9 58.3 57.5 60.3  67 
Gender      100 55.6 52.6  70 85.7  75  100 83.3 
Manukau 
Ethnicity      0 55.6 42.1  60 64.3  75  50 66.7 
Age      63      79  
Gender      100      100  
Mid Cen. 
Ethnicity      0      100  
Age       67.5  46.5  54    50 
Gender       100  100  63.6    100 
Hutt 
Ethnicity       100  50  72.7    100 
Age          70   
Gender          0   
Nelson 
Ethnicity          100   
Note: Gender refers to the percentage of males in the sample receiving a stent Ethnicity refers to the 
percentage of stent recipients who describe themselves as NZ European.  
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5.1.2  Access to the new technology varies according to ethnicity 
and where you live… 
Appendix Tables 2 and 3 (attached) standardise the number of stent procedures for 
patients per 1000 of the population based on their domicile DHB. Appendix Table 2 shows 
the cumulative figure of stent procedures for the period 1995-2004 whereas the Appendix 
Table 3 provides the last complete year of data (2003). This raises several important 
points. First, when looking at the cumulative figures for stents, the standardised number of 
stents for Maori and Pacific Island people consistently falls short of that of NZ Europeans. 
Furthermore, this disparity is at its greatest for people living in DHBs in the South Island. 
However, when 2003 data is taken in isolation, these disparities narrow. One would not 
want to put a large weight on this particular point given that the analysis is based on small 
numbers and is not standardised for age. For instance, the total population of DHBs on 
the South Island is 906 744 with Maori and Pacific Island people constituting just 79 533 
i.e. 8.77% of the population. A much higher proportion of the Maori and Pacific Island 
populations is younger than 20, than of the NZ European population so one would expect 
a lower rate of cardiac procedures compared with NZ Europeans. Nevertheless, it is worth 
flagging at this stage. 
5.1.3  Access to a well established technology also varies 
according to ethnicity and domicile DHB.      
Appendix Tables 4 and 5 (attached) standardise the number of CABGs for patients per 
1000 of the population based on their domicile DHB. Appendix Table 4 shows the 
cumulative figure of CABGs for the period 1995-2004 with Appendix Table 5 showing the 
last complete year of data (2003). As with stents, disparities exist between ethnic groups. 
However, these are equally large across the entire country. When looking at the 2003 
data alone, there are domicile DHBs in which the standardised number of CABGs is the 
same or greater for the Maori and Pacific Island community than for the NZ Europeans 
(Northland, Auckland, Capital and Coast, South Canterbury and Southland). Again, this is 
based on small numbers and data that has not been age standardised but is worth noting 
and monitoring for future years since this may suggest that balance is being redressed.  
5.1.4  The new technology is most likely to be found in hospitals 
where patient volume is high and where there are teaching 
and research links… 
In tracing the spread of the new technology, Table 8 shows the district health boards in 
which stents have been performed and the number of admissions. Clearly this is 
dominated by the “Big 5” but there are other smaller DHBs which have also at some stage 
offered the procedure.  
WP 06/05   
INVESTIGATING HEALTH TECHNOLOGY DIFFUSION IN 




Table 8 – The Number of Admissions for Stent Procedure 
District Health Board  No. of Admissions 
Auckland   6114 





Hutt Valley  17 
Mid Central  2 
Nelson and Marlborough  1 
Total 18942 
Table 9 breaks the admission numbers down by year and hence shows the dispersal of 
the technology. This shows that the pioneers were Auckland, Capital and Coast, Otago 
and Waikato in 1995 with Christchurch following suit in 1998. Closer examination shows 
the hospitals that were responsible.  
Appendix Table 6 provides an interesting story. Clearly, a number of Auckland hospitals 
have used the technology (National Womens, Greenlane, Auckland and Auckland City). 
However, Auckland City Hospital opened in 2003 and brought together the services of 
Auckland, Greenlane and National Womens Hospitals into one building. The general trend 
in the DHB has been a steady increase in this procedure. The other main facilities have 
been Wellington, Waikato, Dunedin and Christchurch Hospitals and these have also seen 
an increase in stenting.  
Table 9 – No. of Stents Performed in each District Health Board 
DHB  1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
Auckland    153 259 509 541 614 711 785 899  1078 565 
Capital  and  Coast  7  67 194 342 355 430 649 679 737 404 
Canterbury  1  5  12 156 549 590 612 649 704 359 
Otago  55 208 326 294 319 320 312 317 363 184 
Waikato  9  43 109 163 261 296 399 439 496 323 
Counties  Manukau  0 0 1 9  19  10  14 8 4 6 
Hutt  Valley  0 0 0 0 2 3  11 0 0 1 
Mid  Central  0 0 0 1 0 0 0 0 1 0 
Nelson    and  Marlborough  0 0 0 0 0 0 0 1 0 0 
Total  225  582 1151 1506 2119 2360 2782 2992 3383 1842 
5.1.5  Stenting has been associated with falling cost weights 
while cost weights have risen for CABGs… 
Table 10 provides the cost weight figures for stents and CABGs for 2000-2004 (the data is 
not available for the period pre-2000). Cost weights are smaller for stents than CABGs, 
with a small reduction in the stent cost weights over the period to 2004. Conversely, 
CABGs are associated with rising cost weights. However, once changes in clinical  
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complexity are noted for both CABGs and stents, it is apparent that the scope of patients 
receiving coronary operations has broadened as procedures become commonplace. 
Table 10 – Aggregate Clinical Complexity and Cost Weight Figures 
  Cost Weights and Clinical Complications for Stents and 
CABGs 
  Stents  CABGs 
  CW  CCL  CW  CCL 
2000  3.296 1.664 7.521 2.394 
2001  2.877 1.673 7.889 2.447 
2002  2.664 1.694 8.362 2.429 
2003  2.67 1.7  8.686  2.55 
2004  2.764 1.747 8.854 2.618 
5.1.6  …but clinical complexity and average age of patients has 
increased.  
Table 11 provides a comparison of clinical complexity and cost weight figures for patients 
receiving stents in each of the DHBs. Clinical complexity has significantly increased for 
the South Island DHBs but remained steady for those in the North. This confirms the 
notion that coverage can be a factor driving health expenditures associated with 
technology. Comparisons may also be drawn with the well established technology, 
CABGs. Appendix Table 7 shows the use of CABGs across different DHBs. Notably, 
neither clinical complexity nor the average age of patients has remained constant over the 
period.  With the exception of Canterbury, where there are no signs of an increase in 
clinical complexity of patients receiving CABGs, each has risen over the period. This 
supports the view that scope has increased not just as a consequence of the introduction 
of stents, but also in a general advancement in technology e.g. improved anaesthetics.   
Table 11 – Clinical Complexity, Cost Weight Figures and Intervention Rates for 
Stents in Different District Health Boards 
DHB  2000  2001  2002  2003  2004* 
  CW  CCL  IR  CW  CCL  IR  CW  CCL  IR  CW  CCL  IR  CW  CCL  IR 
Auckland  3.14 1.78 0.19 2.87  1.8 0.21 2.67 1.84 0.24 2.77 1.77 0.29 2.71 1.78 0.31 
Counties  Manukau  3.09  1.2 0.00 2.95 1.29 0.00 3.12 2.13 0.00 2.55  1 0.00 2.69  2 0.00 
Waikato  3.29 1.73 0.09 3.08 1.62 0.13 2.77  1.7 0.14  2.8 1.56 0.16 2.75 1.65  0.2 
Mid  Central            2.24  1  0.00    
Hutt  3.07 1.33 0.00 2.88 1.09 0.00             2.92  1 0.00 
Capital  and  Coast  3  1.5 0.17 2.57 1.36 0.26 2.46 1.35 0.28 2.53  1.4  0.3 2.74 1.54 0.33 
Nelson-










Canterbury  3.64  1.6 0.14 3.13 1.81 0.14 2.82 1.76 0.15 2.77 1.97 0.16 2.88 1.96 0.17 
Otago  3.43  1.7 0.19 2.77 1.86 0.18 2.61 1.86 0.19 2.55 1.77 0.21 2.68 1.85 0.22 
* denotes half a calendar year of data. The intervention rate has been altered to take account of the smaller 
sample of data. Intervention rates refer to the number of people in the DHB receiving a stent as a percentage 
of the total population in the DHB.  
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6  Concluding Comments – Policy Issues 
There are a number of issues arising from the findings of this analysis: 
First, are the issues of cost- and clinical effectiveness. While the stent itself is cheaper 
than performing a CABG, the evidence has shown that it is associated with an increase in 
coverage thus generating an increase in health expenditure. However, this study does not 
take into account the associated benefits of a healthier workforce, reduced morbidity and 
mortality rates which clearly need to come into the equation when deciding whether to 
adopt a particular technology.  
Second, there is the question of who benefits from the technologies and whether these 
benefits are accessible to all (and indeed whether they need to be!). In the case of 
coronary care, the evidence suggests that groups other than NZ European are 
underrepresented in the data so this calls into question (a) whether technology is 
disseminating appropriately or (b) whether the access problems exist at the primary care 
level hence a smaller number of referrals for coronary procedures. 
6.1.1  There is a trade off between regulating the spread of a new 
technology and providing incentives for innovation 
As outlined in the literature survey, we face a difficult trade off. If technological advances 
are constrained by too many layers of bureaucracy, this is likely to act as a deterrent to a 
number of valuable advances. Until recently, the set up in New Zealand allowed for new 
technologies to spread with little or no regulation (e.g. drug eluting stents). As such, more 
costly procedures could disseminate the market with only limited evidence supporting their 
use.  
In May 2005, the National Health Committee put together a report to the Minister of Health 
setting out recommendations for a health intervention process (Decision Making about 
New Health Interventions, 2005). The Ministry of Health and DHBNZ have subsequently 
put into place the Service Planning and New Health Intervention Assessment (SPNHIA). 
The new procedures call for a more collaborative decision making process between 
DHBs, the Ministry of Health and other related bodies.  
The process has already been trialled in the provision of brachytherapy (a procedure in 
which radioactive material is placed directly into or near the cancer. The radiation is 
sealed in needles, seeds, wires, or catheters.) To date, the process has been deemed a 
success with brachytherapy now reaching the third phase of the process. However, there 
are critics who note that there are too many layers of bureaucracy and hence the process 
is longer than it need be. 
One may also argue that a technology may be introduced into medicine, highly regarded 
and disseminated widely yet clinical and cost evidence can only follow with a considerable 
lag. It is too early to say whether stents demonstrate long term efficacy or differ 
significantly from a clinical or overall cost basis from other coronary procedures. 
Meanwhile, James Harris has suggested that we meld some of the positive features of the 
UK’s National Institute for Clinical Excellence (NICE) and PHARMAC. In particular he 
points to NICE’s breadth of scope and PHARMAC’s ability to negotiate over price, its  
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evaluation and budgetary processes. Together this could improve New  Zealand’s 
resource allocations through a national technology assessment process.  
While an institution like PHARMAC is not always popular with clinicians, it has proven 
success for dealing with drug companies and constraining costs. In its recent publication 
(Annual Review 2004) it compares pharmaceutical costs with what would have emerged 
in the absence of regulation. The volume of drugs prescribed has climbed steadily with 
costs remaining stable in recent years. It will be interesting to see if the new SPNHIA  
process is able to deliver this type of service. 
6.1.2 Final  Comments 
Empirical evidence suggests that technology changes account for a significant proportion 
of health expenditure. While key studies for New  Zealand are scarce, early findings 
suggest that it is likely that new interventions play just as significant a role in health 
spending as for other countries (Bryant et al., 2004). However, at present New Zealand’s 
framework for assessing new interventions is still in its infancy. As such this paper 
provides the first steps in analysing the way in which new technologies reach patients. 
Clearly, there are still a number of issues to be addressed and much work to be 
performed in the area. However, it is hoped that by examining technology advances in the 
cardiac area we will shed light on how the current system works and how processes can 
be made more efficient in the future.  
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Glossary of Terms 
Coronary Angioplasty – ‘Angio’ means artery and ‘plasty’ means opening. This is the 
procedure used to widen the narrowing in a coronary artery with a special balloon. The 
narrowing is caused by a build up of fatty deposits in the walls of the arteries. A catheter 
with a deflated balloon attached to the tip, is passed into the coronary artery under x-ray 
guidance. A coronary angiogram is performed and the balloon is positioned within the 
narrowed artery. The balloon is then inflated widening the artery and improving blood flow. 
Occasionally an angioplasty is performed as an emergency procedure to try to improve 
blood flow during a heart attack. 
Coronary Artery Bypass Graft (CABG) – This is an operation to bypass a narrowed or 
blocked segment of a coronary artery using a graft. CABG surgery is performed primarily 
to relieve angina symptoms. 
Percutaneous Transluminal Coronary Angioplasty (PTCA) – Angioplasty (with or 
without a stent) is also known as PTCA or Percutaneous Coronary Intervention. 
Revascularisation – This describes the procedure for either opening up existing blood 
vessels (through angioplasty) or bypassing the blockage of the coronary arteries (through 
a coronary artery bypass graft). 
Stents – A stent can also be inserted at the time of the angioplasty. It is a metal mesh or 
coil tube that can be inserted into the narrowed artery. It acts as a scaffold by widening 
the artery and keeping it open. Stents are argued to be superior in the long term 
compared with angioplasty.  
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Appendix Table 1 – The Domicile DHB and Agency of Each Separate Admission 
































































































































































































































Northland  1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Waitemata  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Auckland  1615  5092  4536  4025  128  52  173  17  1035  200  34 4  15 9 4  18 5  159 2 8 3  168 
Counties Manukau  0 1 5  102 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 
Waikato  11 15 10 27  4256  1009  2018  345 27  784 10 13  4  5  1  2  1 11 13  4  7 28 
Lakes  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Bay of Plenty  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Tairawhiti  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hawkes Bay  0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 1 0 0 0 
Taranaki  0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 
Mid Central  0 0 0 0 0 0 0 0 1 1  14 0 0 0 0 0 0 0 0 0 0 0 
Whanganui  0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 
Capital and Coast  8 3 6 2 5 5  10 4  915  95  1139  621  2628  1405  411  1333  32  14 1 3 1  163 
Hutt  0 0 0 0 0 0 0 0 0 0 0 0 1  41 0 0 0 1 0 0 0 0 
Wairarapa  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Nelson  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  25 2 0 0 0 0 1 
West Coast  15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
Canterbury  1 1 4 1 4 3 3 0 4 1 5 1 3 3 0  29  281  5035  332  19 8  57 
Canterbury (HLS)  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4  26 0 0 0 0 
S. Canterbury  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
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Otago  1 4 2 0  15 2  13 1 5 4 1 0 1 2 1  40  201  2441  422  3718  1349  246 
Southland  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Heart Surgery South Island  0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0  20  37  353  160 1 
Mercy Auckland  0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 1 0 0 0 
St Georges  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
Wakefield Hospital  0 0 0 0 0 0 0 0 3 0  14 1  15 8 2 4 0 0 0 0 0 0 
Not specified  0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Western Bay Health  0 0 0 0 0 1  14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
East Bay Health  0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
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Appendix Table 2 –Cumulative Figures for Stent Operations between 1995 and 2004 
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No of Stents 
Per 1000 of 
Maori & 
Pacific 
Northland  600  140127  4.3 46299 93828  43890  455  145  3.1  4.8  78  1.8 
Waitemata  1899 429756  4.4 131529 298227 72624  1391  508  3.9  4.7  99  1.4 
Auckland  1760 367734  4.8 160797 206937 80370  1151  609  3.8  5.6  159  2.0 
C.  Manukau  1509 375531  4.0 185250 190281  143814  969  540  2.9  5.1  232  1.6 
Waikato  1334 317751  4.2 127470 190281 74454  1046  288  2.3  5.5  100  1.3 
Bay of Plenty  573  178161  3.2  47487  130674  45912  419  154  3.2  3.2  49  1.1 
Lakes  321 95994  3.3 33423 62571  33975  236  85  2.5  3.8  36  1.1 
Tairawhiti  87 43971  2.0 18630 25341  20592  57  30  1.6  2.2  26  1.3 
Taranaki  293  103023  2.8 16431 86592  15732  243  50  3.0  2.8  18  1.1 
Whanganui  304 63594  4.8 15009 48585  15372  232  72  4.8  4.8  21  1.4 
Mid Central  476  154986  3.1  30276  124710  27777  354  122  4.0  2.8  27  1.0 
Hawkes Bay  843  143547  5.9  37908  105639  37380  688  155  4.1  6.5  74  2.0 
Wairarapa 183  38208  4.8  5973  32235  6258  148  35  5.9  4.6  5  0.8 
Hutt  607  131847  4.6 35988 95859  30447  429  178  4.9  4.5  43  1.4 
Capital and Coast  1246  245880  5.1  72246  173634  47148  732  514  7.1  4.2  94  2.0 
Nelson-Marlborough 513  122472 4.2  15795  106677  11211  436  77  4.9  4.1  20 1.8 
West Coast  198  30294  6.5  3393  26901  2757  169  29  8.5  6.3  3  1.1 
Canterbury 3484  427083  8.2  65943  361140  37425  2567  917  13.9  7.1  75  2.0 
South Canterbury  313  52785  5.9  4371  48414  3219  271  42  9.6  5.6  9  2.8 
Otago 1612  170739  9.4  20505  150234  12666  1361  251  12.2  9.1  38  3.0 
Southland  573  103371  5.5 12381 90990  12255  498  75  6.1  5.5  21  1.7 
Overseas  214         101       7   
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Appendix Table 3 – Stent Operations: Figures for Last Complete Year of Data (2003) 
District Health 































Per 1000 of 
Non-NZ 
Europ’n 
No of  
Stents  
Per 1000 of 
NZ Europ’n 







Per 1000 of 
Maori & 
Pacific 
Northland  109  140127 0.8  46299  93828  43890  82  27 0.6 0.9  14 0.3 
Waitemata  359 429756  0.8 131529 298227  72624  234  125  1.0  0.8  20  0.3 
Auckland  309 367734  0.8 160797 206937  80370  166  143  0.9  0.8  39  0.5 
C.  Manukau  264 375531  0.7 185250 190281 143814  138  126  0.7  0.7  59  0.4 
Waikato  239 317751  0.8 127470 190281  74454  182  57  0.4  1.0  22  0.3 
Bay  of  Plenty  122  178161 0.7  47487  130674  45912  97  25 0.5 0.7  16 0.3 
Lakes  68 95994  0.7 33423 62571 33975  53  15  0.4  0.8  11  0.3 
Tairawhiti  23 43971  0.5 18630 25341 20592  17  6  0.3  0.7  6  0.3 
Taranaki  51  103023 0.5  16431  86592  15732  43  8 0.5 0.5  5 0.3 
Whanganui  64 63594  1.0 15009 48585 15372  46  18  1.2  0.9  5  0.3 
Mid  Central  84  154986 0.5  30276  124710  27777  61  23 0.8 0.5  8 0.3 
Hawkes  Bay  149  143547 1.0  37908  105639  37380  127  22 0.6 1.2  1 0.0 
Wairarapa  30  38208 0.8  5973  32235  6258  25  5 0.8 0.8  2 0.3 
Hutt  104  131847 0.8  35988  95859  30447  76  28 0.8 0.8  7 0.2 
Capital  and  Coast  219  245880 0.9  72246  173634  47148  128  91 1.3 0.7  27 0.6 
Nelson-Marlborough  107  122472 0.9  15795  106677  11211  91  16 1.0 0.9  9 0.8 
West  Coast  41  30294 1.4  3393  26901  2757  37  4 1.2 1.4  0 0.0 
Canterbury  599  427083 1.4  65943  361140  37425  411  188 2.9 1.1  14 0.4 
South  Canterbury  59  52785 1.1  4371  48414  3219  46  13 3.0 1.0  4 1.2 
Otago  244  170739 1.4  20505  150234  12666  200  44 2.1 1.3  10 0.8 
Southland  109  103371 1.1  12381  90990  12255  91  18 1.5 1.0  5 0.4 
Overseas  30       6  24    3   
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Appendix Table 4 – Cumulative Figures for CABG Operations between 1995 and 2004 
District Health 































Per 1000 of 
Non-NZ 
Europ’n 
No of  
CABGs Per 
1000 of NZ 
Europ’n 







Per 1000 of 
Maori & 
Pacific 
Northland  675  140127  4.8 46299 93828 43890  488  187  4.0  5.2  112  2.6 
Waitemata  1831 429756  4.3 131529 298227  72624  1332  499  3.8  4.5  130  1.8 
Auckland  1638 367734  4.5 160797 206937  80370  1049  589  3.7  5.1  230  2.9 
C.  Manukau  1528 375531  4.1 185250 190281 143814  969  559  3.0  5.1  278  1.9 
Waikato  1419 317751  4.5 127470 190281  74454  1109  310  2.4  5.8  122  1.6 
Bay of Plenty  844  178161  4.7  47487  130674  45912  592  252  5.3  4.5  62  1.4 
Lakes  360 95994  3.8 33423 62571 33975  240  120  3.6  3.8  62  1.8 
Tairawhiti  139 43971  3.2 18630 25341 20592  81  58  3.1  3.2  46  2.2 
Taranaki  423  103023  4.1 16431 86592 15732  363  60  3.7  4.2  17  1.1 
Whanganui  218 63594  3.4 15009 48585 15372  163  55  3.7  3.4  15  1.0 
Mid  Central  446  154986  2.9 30276  124710 27777  340  106  3.5  2.7  27  1.0 
Hawkes  Bay  681  143547  4.7 37908  105639 37380  548  133  3.5  5.2  67  1.8 
Wairarapa  141  38208  3.7 5973  32235 6258  119  22  3.7  3.7  9  1.4 
Hutt  495  131847  3.8 35988 95859 30447  319  176  4.9  3.3  51  1.7 
Capital and Coast  717  245880  2.9  72246  173634  47148  410  307  4.2  2.4  52  1.1 
Nelson-Marlborough  569  122472  4.6 15795  106677 11211  493  76  4.8  4.6  15  1.3 
West  Coast  153  30294  5.1 3393  26901 2757  133  20  5.9  4.9  3  1.1 
Canterbury  2007  427083  4.7 65943  361140 37425  1561  446  6.8  4.3  59  1.6 
South  Canterbury  251  52785  4.8 4371  48414 3219  217  34  7.8  4.5  2  0.6 
Otago  1116  170739  6.5 20505  150234 12666  953  163  7.9  6.3  22  1.7 
Southland  524  103371  5.1 12381 90990 12255  433  91  7.3  4.8  29  2.4 
Overseas  245       152  93      
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Appendix Table 5 – CABG Operations: Figures for Last Complete Year of Data (2003) 
District Health 
















































of Maori & 
Pacific 
Northland  86  140127  0.6 46299 93828 43890  52  34  0.7  0.6  28  0.6 
Waitemata  190  429756  0.4  131529  298227  72624  115 75  0.6  0.4 23  0.3 
Auckland  173  367734  0.5  160797  206937  80370 91 82  0.5  0.4 31  0.4 
C.  Manukau  181 375531  0.5 185250 190281 143814  107  74  0.4  0.6  39  0.3 
Waikato  145  317751  0.5  127470  190281  74454  114 31  0.2  0.6 12  0.2 
Bay of Plenty  93  178161  0.5  47487  130674  45912  73  20  0.4  0.6  8  0.2 
Lakes  37 95994  0.4 33423 62571 33975  23  14  0.4  0.4  9  0.3 
Tairawhiti  18 43971  0.4 18630 25341 20592  10  8  0.4  0.4  7  0.3 
Taranaki  41  103023  0.4 16431 86592 15732  36  5  0.3  0.4  1  0.1 
Whanganui  39 63594  0.6 15009 48585 15372  32  7  0.5  0.7  2  0.1 
Mid Central  71  154986  0.5  30276  124710  27777  57  14  0.5  0.5  6  0.2 
Hawkes  Bay  83  143547  0.6  37908  105639  37380 62 21  0.6  0.6 15  0.4 
Wairarapa  19  38208  0.5  5973  32235  6258  17 2  0.3  0.5 1  0.2 
Hutt  59  131847  0.4 35988 95859 30447  39  20  0.6  0.4  10  0.3 
Capital and Coast  81  245880  0.3  72246  173634  47148  42  39  0.5  0.2  14  0.3 
Nelson-Marlborough  72  122472  0.6  15795  106677  11211  65 7  0.4  0.6 1  0.1 
West  Coast  13  30294  0.4  3393  26901  2757  12 1  0.3  0.4 0  0.0 
Canterbury  239  427083  0.6  65943  361140  37425  174 65  1.0  0.5 10  0.3 
South Canterbury  23  52785  0.4  4371  48414  3219  13  10  2.3  0.3  2  0.6 
Otago 117  170739  0.7  20505  150234  12666  104  13  0.6  0.7  1  0.1 
Southland  67  103371  0.6 12381 90990 12255  51  16  1.3  0.6  7  0.6 
Overseas  18       1  17    12   
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Appendix Table 6 – The Spread of Technology: The Case of Stents 
Facility    1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
No of Stents  153  259  138 0 0 0 0 0 0 0 
Length of Stay  5.48  4.05  3.07        
Average Age  58.81  61.19  61.41        
Auckland 
National Womens 
Clinical Complications            
No of Stents  0  0 371 537 611 705 785 897 489  0 
Length of Stay     3.28 3.31 2.61 2.61 2.45 2.49 2.48   
Average Age     60.36 59.93 59.73 60.48 61.54 62.17 62.05   
Auckland 
Greenlane 
Clinical Complications        1.7 1.72 1.78 1.80 1.84 1.74   
No of Stents  0 0 0 5 3 6 0 2 0 0 
Length of Stay       3.75 4.67 4.50   4.50     
Average Age       61.75 62.33 56.17   59.50     
Auckland 
Clinical Complications      1  1  1.5   2.5   
No of Stents  0 0 0 0 0 0 0 0  582  565 
Length of Stay           2.38  2.95 
Average Age           60.54  61.73 
Auckland City 
Hospital 
Clinical Complications           1.82  1.78 
No of Stents  7  67 194 342 355 429 649 679 737 404 
Length of Stay  4.86 2.36 2.39 2.45 2.07 1.87 1.55 1.59 1.48 1.85 
Average Age  56.38 58.64 60.09 61.88  61.4 60.77 61.55 61.54 61.89 61.34 
Capital & Coast 
Wellington 
Clinical Complications       1.28 1.37 1.50 1.36 1.35 1.40 1.54 
No of Stents  0 0 0 0 0 1 0 0 0 0 
Length of Stay        1 3      
Average Age        8 0      
Capital & Coast 
Kenepura 
Clinical Complications        4      
No of Stents  1  5  12 156 549 590 612 649 704 359 
Length of Stay  8 5.20 7.33 7.46 5.67 6.24  5.5 5.32 4.76  5.2 
Average Age  42 58.00 54.17 60.44 62.56 63.02 62.64 62.09 63.43 63.06 
Canterbury 
Christchurch 
Clinical Complications       1.73 1.69  1.6 1.81 1.76 1.97 1.96 
No of Stents  55 208 326 294 319 320 312 317 363 184 
Length of Stay  6.35 4.26 4.08 3.19 3.38 4.04 3.37 3.58 3.48 3.72 
Average Age  63.16 58.41 61.08 60.34 61.28 61.77  62.8 63.13 64.62 63.76 
Otago Dunedin 
Clinical Complications       1.70 1.84  1.7 1.86 1.86 1.77 1.85 
No of Stents  9  43 109 163 261 296 399 439 496 323 
Length of Stay  9.22 5.72 5.75 5.02 4.88 4.67 4.57 4.49 4.07 4.03 
Average Age  58.22 57.79  59.3 60.15 62.27 61.74 61.99 60.71 61.67 62.18 
Waikato 
Clinical Complications       1.58 1.88 1.73 1.62  1.7 1.56 1.65 
No of Stents  0 0 1 9  19  10  14 8 4 5 
Length of Stay      8  5 5.26 4.70 5.43 5.75 8.25 7.60 
Average Age      57 59.33 55.37 56.90 58.29  57.5 60.25 67.40 
Manukau 
Clinical Complications       1.33 1.74 1.20 1.29 2.13 1.00 2.00  
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Facility    1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
No of Stents  0 0 0 1 0 0 0 0 1 0 
Length of Stay      2      1  
Average Age      63      79  
Mid Central 
Palmerston North 
Clinical Complications      2      1  
No of Stents  0 0 0 0 2 3  11 0 0 1 
Length of Stay       21  5.33  3    2 
Average Age       67.50  52.67  54.00    50 
Hutt Valley  
Hutt Hospital 
Clinical Complications       3.00  1.33  1.09    1 
No of Stents  0 0 0 0 0 0 0 1 0 0 
Length of Stay          1    
Average Age          7 0    
Nelson 
Marlborough 
Clinical Complications          3    
No of Stents  0 0 0 0 0 0 0 0 7 0 
Length of Stay           0   
Average Age           63.86  
Mercy, Auckland 
Clinical Complications           0.43   
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Appendix Table 7 – The Use of an Older Technology across Different DHBs: The 
Case of CABGs 
Facility    1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
No of CABGs  502 467 641 697 702 670 776 817 681 281 
Length of Stay  13.24 13.36 12.28 12.32 11.74 11.99 11.02 11.64 11.88 13.46 
Average Age  62.64 64.21 63.41 63.87  64 64.34 65.18 64.87 64.34 65.42 
Auckland 
Clinical Complications       2.68 2.65 2.71 2.56 2.63 2.62 2.87 
No of CABGs  233 207 213 266 295 465 318 338 397 159 
Length of Stay  12.82  12.8 12.97 11.52 10.46  9.53 10.26 10.99  9.87  9.84 
Average Age  62.34  62.6 63.66 64.29 63.46 63.54 63.49 65.21 65.13 63.91 
Capital & Coast 
Clinical Complications       2.05  1.7 1.72  2.2 1.99 2.19 2.15 
No of CABGs  0  0  5 141 224 263 256 244 275 141 
Length of Stay      7.6 15.79 18.38 16.52 17.07 12.32 14.72  16.1 
Average Age      62.2  63.8 65.11 65.31  65 64.65 65.29 64.54 
Canterbury 
Clinical Complications       2.76 2.69 2.42  2.5 2.46 2.67 2.62 
No of CABGs  371 349 429 281 128  35  17 156 186  85 
Length of Stay  13.67 13.69 12.22 13.06 11.96 11.14  9.59 13.23 16.52 13.45 
Average Age  63.75 63.58 64.81 64.65 65.08 66.89 67.47 66.99 66.03 65.69 
Otago 
Clinical Complications       2.83 3.01 2.94 2.11 2.67 3.01 2.72 
No of CABGs  284 355 317 287 316 341 398 339 326 153 
Length of Stay  12.17 12.26 14.95 14.45 14.06 14.54  14.1 13.74  14.7 16.11 
Average Age  63.16 61.43 64.39 63.75 64.47 63.24 63.63 64.18 64.58  64.6 
Waikato 
Clinical Complications       2.39 2.59  2.4 2.26 2.16 2.47 2.57 
No of CABGs  0 0 1 0 0 0 0 0 0 0 
Length of Stay     7         
Average  Age     66        
Manukau 
Clinical  Complications            
No  of  CABGs  0 0 0 0 0 0 0 0 0 0 
Length  of  Stay            
Average  Age            
Hawkes Bay 
Clinical Complications            
No of CABGs  24 0 0 0 0 0 2 0 0 0 
Length of Stay  8.42       7.5    
Average Age  60.39       58    
Wakefield 
Clinical Complications         0     
No of CABGs  0 0 0 1 0 0 0 0 0 0 
Length of Stay      1 0        
Average Age      7 6        
Taranaki 
Clinical Complications            
No of CABGs  0 0 0 7 0 0 0 0 0 0 
Length of Stay      8.86       
Average Age      63.71       
Mercy, Auckland. 
Clinical Complications             
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Facility    1995  1996  1997  1998  1999  2000  2001  2002  2003  2004 
No of CABGs  0 0 0 0  95  188  197  77 0 0 
Length of Stay       8.52  9.87  9.33  8.9   
Average Age       65.59  65.09  66.66  67.27   
Heart Surgery Sth 
Island 
Clinical Complications       2.45  2.79  2.74  2.75   
No of CABGs  0 0 0 0 0 0 0 0 0 1 
Length of Stay            2 2  
Average Age            6 9  
St Georges 
Clinical Complications            2  
 